Page last updated: 2024-12-11

laniquidar

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth Market Indicators

Description

laniquidar: structure in first source [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]

Cross-References

ID SourceID
PubMed CID6450806
CHEMBL ID539378
SCHEMBL ID1649844
MeSH IDM0367050

Synonyms (22)

Synonym
laniquidar
CHEMBL539378
methyl 11-[1-[2-[4-(quinolin-2-ylmethoxy)phenyl]ethyl]piperidin-4-ylidene]-5,6-dihydroimidazo[2,1-b][3]benzazepine-3-carboxylate
5h-imidazo(2,1-b)(3)benzazepine-3-carboxylic acid, 6,11-dihydro-11-(1-(2-(4-(2-quinolinylmethoxy)phenyl)ethyl)-4-piperidinylidene)-, methyl ester
r-101933
k3frn4ddoy ,
11c-laniquidar
methyl 6,11-dihydro-11-(1-(2-(4-(-2-quinolylmethoxy)phenyl)ethyl)-4-piperidinylidene)-5h-imidazo(2,1-b)(3)benzazepine-3-carboxylate
197509-46-9
unii-k3frn4ddoy
laniquidar [inn]
methyl 6,11-dihydro-11-[1-[2-[4-(2-quinolinylmethoxy)phenyl]ethyl]-4-piperidinylidene]-5h-imidazo[2,1-b][3]-benzazepine-3-carboxylate
TULGGJGJQXESOO-UHFFFAOYSA-N
laniquidar [who-dd]
SCHEMBL1649844
methyl 11-(1-(4-(quinolin-2-ylmethoxy)phenethyl)piperidin-4-ylidene)-6,11-dihydro-5h-benzo[d]imidazo[1,2-a]azepine-3-carboxylate
DTXSID10173436
DB12799
Q6487103
gtpl11789
HY-132189
CS-0169675

Research Excerpts

Overview

Laniquidar is a third-generation P-gp inhibitor. It has been used in clinic trials for modulating multidrug resistance transporters.

ExcerptReferenceRelevance
"Laniquidar is a third-generation P-gp inhibitor, which has been used in clinic trials for modulating multidrug resistance transporters."( Evaluation of [11C]laniquidar as a tracer of P-glycoprotein: radiosynthesis and biodistribution in rats.
Klok, RP; Lammertsma, AA; Leysen, JE; Luurtsema, G; Schuit, RC; Verbeek, J; Windhorst, AD, 2009
)
1.4

Bioavailability

ExcerptReferenceRelevance
"Irinotecan (CPT-11) is a camptothecin analog with low (about 10--20%) and variable oral bioavailability in animal models."( Active transepithelial transport of irinotecan (CPT-11) and its metabolites by human intestinal Caco-2 cells.
de Bruijn, P; de Jonge, MJ; Kurihara, M; Nishiyama, M; Sparreboom, A; Takano, H; Verweij, J; Yamamoto, W, 2001
)
0.31
" However, due to the low oral bioavailability of R101933 and high interpatient variability, no further attempts to increase the level of P-gp inhibition were made."( Disposition of docetaxel in the presence of P-glycoprotein inhibition by intravenous administration of R101933.
Bol, CJ; Brouwer, E; de Vries, R; Eskens, FA; Nooter, K; Palmer, PA; Sparreboom, A; van der Gaast, A; van Zuylen, L; Verweij, J, 2002
)
0.31
"P-glycoprotein inhibitors can increase the oral bioavailability of paclitaxel."( Efficacy of novel P-glycoprotein inhibitors to increase the oral uptake of paclitaxel in mice.
Bardelmeijer, HA; Beijnen, JH; Ouwehand, M; Schellens, JH; van Tellingen, O, 2004
)
0.32
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Bioassays (1)

Assay IDTitleYearJournalArticle
AID419513Volume of distribution at steady state in human at 50 mg, iv2009Journal of medicinal chemistry, Jul-23, Volume: 52, Issue:14
In silico prediction of volume of distribution in human using linear and nonlinear models on a 669 compound data set.
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (13)

TimeframeStudies, This Drug (%)All Drugs %
pre-19900 (0.00)18.7374
1990's0 (0.00)18.2507
2000's9 (69.23)29.6817
2010's4 (30.77)24.3611
2020's0 (0.00)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Market Indicators

Research Demand Index: 19.64

According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be moderate demand-to-supply ratio for research on this compound.

MetricThis Compound (vs All)
Research Demand Index19.64 (24.57)
Research Supply Index2.77 (2.92)
Research Growth Index4.78 (4.65)
Search Engine Demand Index15.26 (26.88)
Search Engine Supply Index2.00 (0.95)

This Compound (19.64)

All Compounds (24.57)

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials2 (15.38%)5.53%
Reviews1 (7.69%)6.00%
Case Studies0 (0.00%)4.05%
Observational0 (0.00%)0.25%
Other10 (76.92%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]